Furthermore, we confirmed that there was a higher increase in CD8 proliferating and CD8 GZMB+ in SD patients and a higher increase in CD8 GZMK+ cells in well response patients upon GOLP treatment in our validation cohorts (NCT03951597 and FDU-ZS-iCCA-T) by mIHC and flow cytometry (Fig. 6F, G). This evidence concerns the gene PRRT2 and Salla disease.